Evidence map›Paper›PMID 36544280›Full record

ArticleTurkish journal of pharmaceutical sciences2022

Advantages and Disadvantages of Two

Elif İnce Ergüç, Senem Özcan Sezer, Hande Gürer Orhan

Open access · diamondAbstract read
In one paragraph

Article in Turkish journal of pharmaceutical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Elif İnce Ergüçİzmir Katip Çelebi University, Faculty of Pharmacy, Department of Pharmaceutical Toxicology, İzmir, Türkiye.ORCID 0000-0003-0764-7694
Senem Özcan SezerEge University, Faculty of Pharmacy, Department of Pharmaceutical Toxicology, İzmir, Türkiye.ORCID 0000-0001-5323-9646
Hande Gürer OrhanEge University, Faculty of Pharmacy, Department of Pharmaceutical Toxicology, İzmir, Türkiye.ORCID 0000-0002-4890-299X
Ege University · TRIzmir Kâtip Çelebi University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Aromatase is an enzyme that catalyzes the conversion of androgens to estrogens. While inhibition of aromatase is a useful approach for treating breast cancer, it may also have toxicological consequences due to its endocrine disrupting/modulating effect. In this study, sensitivity and performance of two Materials and Methods: Aromatase activity was evaluated Results: In the cell-free direct measurement assay, reference compounds ketoconazole and aminoglutethimide have been shown to inhibit the aromatase enzyme with half-maximal inhibitory concentration (IC Conclusion: Both methods can be successfully applied. However, to evaluate the potential aromatase activity of the novel compounds

Indexed as

Aromatase inhibitioncell-based assaycell-free assayin vitro

Identifiers

PMID36544280
PMCPMC9780571
OpenAlexW3215508910

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.